EAM
CTMX icon

Exome Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Exome Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Sell
521,468
-223,837
-30% -$1.14M 1.27% 34
2025
Q4 		$3.17M Hold
745,305
– – 1.52% 27
2025
Q3 		$2.38M Buy
+745,305
New +$1.68M 1.44% 29

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Exome Asset Management's CTMX Position: Q1 2026 in Review

Exome Asset Management reduced its CytomX Therapeutics (CTMX) stake by 30% in Q1 2026, selling an estimated $1.14M and leaving 521,468 shares worth $2.45M. The position accounts for 1.27% of the portfolio, ranked #34.

Exome Asset Management first reported a position in CTMX in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.17M in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Exome Asset Management held 521,468 shares of CytomX Therapeutics worth $2.45M as of Q1 2026.
  • Exome Asset Management sold 223,837 CytomX Therapeutics shares in Q1 2026, an estimated $1.14M.
  • CytomX Therapeutics made up 1.27% of Exome Asset Management's portfolio in Q1 2026, its #34 holding.
  • Exome Asset Management first reported a position in CytomX Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Exome Asset Management's CytomX Therapeutics position peaked at $3.17M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.